Atlas Venture's Quartet aims to harness the immune system to make painkillers

While one of the hottest areas of cancer drug development is based on an approach that uses the body's immune system, a handful of investors are making a $17 million bet on a Cambridge biotech aiming to take a similar approach to pain management. Quartet Medicine, founded last year at Atlas, launched today with plans to create pills that could be more effective than Lyrica, a drug marketed by Pfizer for neuropathic pain, such as that felt in diabetic neuropathy, and shingles. The approach is based…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news